AUROBINDO PHARMA LTD. - 524804 - Business Responsibility and Sustainability Reporting (BRSR)
Business Responsibility and Sustainability Report for the financial year 2022-23 is attached.01-08-2023
01-08-2023
AUROBINDO PHARMA LTD. - 524804 - Reg. 34 (1) Annual Report.
Annual Report for the financial year 2022-23 is attached01-08-2023
AUROBINDO PHARMA LTD. - 524804 - Notice Of 36Th Annual General Meeting To Be Held On Friday, August 25, 2023
Notice of 36th Annual General Meeting to be held on Friday, August 25, 202301-08-2023
Aurobindo Pharma gets USFDA approval for Saxagliptin tablets, plans immediate launch
Aurobindo Pharma is eligible for 180 days of shared generic drug exclusivity for Saxagliptin tablets01-08-2023
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
We enclose a press release that is being issued in connection with USFDA approval received by the Company.01-08-2023
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Newspaper Publication
News Paper advertisement informing shareholders about the 36th Annual General Meeting to be held on Friday, 25th August 2023.30-07-2023
AUROBINDO PHARMA LTD. - 524804 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate and issue of duplicate share certificate.28-07-2023
AUROBINDO PHARMA LTD. - 524804 - Book Closure For The Purpose Of 36Th Annual General Meeting Of The Company To Be Held On August 25, 2023.
The Register of members and share transfer books will be closed from August 23, 2023 to August 25, 2023 for the purpose of 36th Annual General Meeting to be held on August 25, 2023.28-07-2023
AUROBINDO PHARMA LTD. - 524804 - 36Th Annual General Meeting Of Aurobindo Pharma Limited - August 25, 2023
36th AGM of the Company will be held on August 25, 2023 at 3.30 PM.28-07-2023
Aurobindo Pharma jumps 91%, others gain up to 94% this year: Why are pharma stocks rising - Explained
Pharma stocks in India have been outperforming the benchmark index Nifty50 this year. Factors driving the gains include improved performance in the US generics market, robust performance in branded markets, lower raw material costs, and market share gains in new products.28-07-2023